NeoStem, Inc. NBS
("NeoStem" or the "Company"), a leader in the fast growing cell therapy
market, today announced that, on September 13, 2013, the Data Safety
Monitoring Board ("DSMB") recommended continuing the PreSERVE AMI Phase 2
clinical trial following a third interim data and safety review. The PreSERVE
trial of AMR-001 is a Phase 2, randomized, placebo controlled, double-blind
study designed to treat 160 patients. AMR-001 is being evaluated for the
preservation of heart function after a severe heart attack.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in